Home » AERIE PHARMACEUTICALS ANNOUNCES $21 MILLION SERIES A FINANCING
AERIE PHARMACEUTICALS ANNOUNCES $21 MILLION SERIES A FINANCING
Aerie Pharmaceuticals, Inc., a biotechnology company focused on the discovery and development of medical innovations in ophthalmology, today announced the closing of a $21 million Series A financing. The syndicate was co-led by Alta Partners and Texas Pacific Group Ventures. In connection with the financing, Geoff Duyk, MD, Ph.D., a managing director at TPG Ventures and David Mack, Ph.D., a director at Alta Partners will join Aerie's board of directors.
Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=1077229XSL_NEWSML_TO_NEWSML_WEB.xml)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May